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Abstract
Background: SARS-CoV-2 is the causative agent of COVID-19, an emergent zoonotic 
disease which has reached pandemic levels and is designated a public health 
emergency of international concern. It is plausible that former or current smoking 
status is associated with infection, hospitalisation and/or mortality from COVID-19.
Objective: We aimed to estimate the association of smoking status with rates of i) 
infection, ii) hospitalisation, iii) disease severity, and iv) mortality from SARS-CoV-
2/COVID-19 disease.
Methods: T his is a living evidence review with frequent updates. We adopted 
recommended practice for rapid evidence reviews, which involved limiting the search 
to main databases and having one reviewer extract data and another verify. Published 
articles and pre-prints were identified via Ovid MEDLINE, medRxiv and expertise within 
the review team. We included observational or experimental studies with community-
dwelling or hospitalised adults aged 16+ years who had received a test for SARS-CoV-2 
infection or a diagnosis of COVID-19, providing that data on smoking status were 
reported. Studies were judged as ‘good’ quality if they: i) had low levels of missing data 
on smoking status (i.e. <20%) and used a reliable self-report measure that 
distinguished between current, former and never smoking status; AND ii) used 
biochemical verification of smoking status and reported results from adjusted 
analyses; OR reported data from a representative/random sample. Studies were rated 
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as ‘fair’ if they fulfilled criterion i) only and were otherwise rated as ‘poor’.
Results: Version 5 with searches up to 23 June 2020 included 148 studies, 43 of which 
were conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight 
in France, six in Italy, five across multiple international sites, two in Israel, and one each 
from 14 further countries. T hirty-two (21.6%) studies reported current, former and 
never smoking status. T wenty-six studies (17.6%) explicitly reported the proportion 
missing data on smoking status, which ranged from 0.08% to 96.4%. Notwithstanding 
recording uncertainties, compared with adult national prevalence estimates, recorded 
current and former smoking rates were generally lower than expected. In 12 ‘fair’ 
quality studies, current smokers were at reduced risk of testing positive for SARS-CoV-
2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p = .003, I2 = 90%). No 
significant difference was observed between former and never smokers (RR = 1.02, 
95% CI = 0.92-1.12, p = .76, I2 = 72%). In seven ‘fair’ quality studies, there was no 
significant difference between current and never (RR = 1.06, 95% CI = 0.79-1.44, p = 
.63, I2 = 79%) or former and never smokers (RR = 1.20, 95% CI = 0.95-1.51, p = .10, I2 
= 79%) in the risk of requiring admission to hospital with COVID-19 among those 
testing positive in the community. In six ‘fair’ quality studies, no significant difference in 
disease severity was observed between current and never smokers (RR = 1.22, 95% CI 
= 0.98-1.53, p = .08, I2 = 22%). Former smokers were at increased risk of greater 
disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, 
I2 = 68%). In five ‘fair’ quality studies, current (RR = 1.70, 95% CI = 1.14-2.55, p = .01, I2 
= 29%) and former smokers (RR = 2.00, 95% CI = 1.57-2.55, p < .0.001, I2 = 0%) were 
at increased risk of in-hospital death compared with never smokers.
Conclusions: Across 148 studies, there is substantial uncertainty about the 
associations of smoking with COVID-19 outcomes. T he recorded smoking prevalence 
in the included studies was generally lower than overall adult national estimates. T here 
was no evidence of reduced risk of admission to hospital for current compared with 
never smokers among those testing positive in the community. T here was some 
evidence that current compared with never smoking is associated with reduced risk of 
testing positive in the community but also greater in-hospital mortality from COVID-
19. T here was some evidence that former compared with never smoking is associated 
with increased risk of greater disease severity and in-hospital mortality from COVID-
19.
Implications: Unrelated to COVID-19, smokers are at a greater risk of a range of 
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serious health problems. Given uncertainty around the association of smoking with 
COVID-19 outcomes, smoking cessation remains a public health priority and high-
quality smoking cessation advice including recommendations to use alternative 
nicotine products should form part of public health efforts during this pandemic. High 
quality, smoking-specific research is needed to resolve these mixed findings.
Introduction
 
COVID-19 is a respiratory disease caused by the emerging SARS-CoV-2 virus. Large age
and gender differences in case severity and mortality have been observed in the ongoing
COVID-19 pandemic1; however, these differences are currently unexplained. SARS-CoV-2
enters epithelial cells through the ACE-2 receptor2. Some evidence suggests that gene
expression and subsequent receptor levels are elevated in the airway and oral epithelium
of current smokers3,4, thus putting smokers at higher risk of contracting SARS-CoV-2.
Other studies, however, suggest that nicotine downregulates the ACE-2 receptor5.
T hese uncertainties notwithstanding, both former and current smoking is known to
increase the risk of respiratory viral6,7 and bacterial8,9 infections and is associated with
worse outcomes once infected. Cigarette smoke reduces the respiratory immune
defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary
clearance and disruption of the respiratory epithelium10. T here is also reason to believe
that behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking
may increase SARS-CoV-2 infection and transmission in current smokers. However, early
data from the COVID-19 pandemic have not provided clear evidence for a negative
impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease
outcomes, such as hospitalisation or mortality11. It has also been hypothesised that
nicotine might protect against a hyper-inflammatory response (or “cytokine storm”) to
SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19
disease12.
 
T here are several reviews that fall within the scope of smoking and COVID-1911,13–17.
We aimed to produce a rapid synthesis of available evidence pertaining to the rates of
infection, hospitalisation, disease severity and mortality from SARS-CoV-2/COVID-19
stratified by smoking status. Given the increasing availability of data on this topic, this is a
living review with regular updates. As evidence accumulates, the review will be expanded
to include studies reporting COVID-19 outcomes by alternative nicotine use (e.g., nicotine
replacement therapy or e-cigarettes).
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Methods
 
Study design
T his is a living evidence review which is updated as new evidence becomes available18.
We adopted recommended practice for rapid evidence reviews, which involved limiting
the search to main databases and having one reviewer extract the data and another
verify19.
Eligibility criteria
 
Studies were included if they:
 
1)      Were primary research studies using experimental (e.g. randomised controlled trial),
quasi-experimental (e.g. pre- and post-test) or observational (e.g. case-control,
retrospective cohort, prospective cohort) study designs;
2)      Included adults aged 16+ years;
3)      Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody
assays), ii) clinical diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity of
COVID-19 disease in those hospitalised or v) mortality from COVID-19;
4)      Reported any of the outcomes of interest by self-reported or biochemically verified
smoking status (e.g. current smoker, former smoker, never smoker);
5)      Were available in English;
6)      Were published in a peer-reviewed journal, as a pre-print or a public health report by
reputable agents (e.g. governments, scientific societies).
 
Search strategy
 
T he following terms were searched for in Ovid MEDLINE as free text or Medical Subject
Headings:
 
1. T obacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or
Smoking Pipes/ or Cigar Smoking/ or Smoking Prevention/ or Cigarette Smoking/ or
smoking.mp. or Pipe Smoking/ or Smoking, Non-T obacco Products/ or Smoking Water
Pipes/
2. Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing
Gum/
3. vaping.mp. or Vaping/
4. 1 or 2 or 3
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5. Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or
covid.mp.
6. 4 and 5
 
T he following terms were searched for in titles, abstracts and full texts in medRxiv:
 
covid smoking
covid nicotine
covid vaping
 
Additional articles/reports of interest were identified through mailing lists, T witter, the
International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), the
Intensive Care National Audit & Research Centre (ICNARC) and the US Centers for
Disease Control and Prevention (CDC).
 
Where updated versions of pre-prints or public health reports were available, old versions
were superseded.
 
Selection of studies
 
One reviewer screened titles, abstracts and full texts against the inclusion criteria.
 
Data extraction
 
Data were extracted by one reviewer and verified by a second on i) author (year); ii) date
published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii) age; ix)
smoking status (e.g. current, former, never, not stated, missing); x) SARS-CoV-2
infection; xi) diagnosis of COVID-19; xii) hospitalisation with COVID-19; xiii) disease
severity in those hospitalised with COVID-19; and xiv) mortality.
 
Quality appraisal
 
In previous review versions, we used the National Institutes of Health’s Quality
Assessment T ool for Observational Cohort and Cross-Sectional Studies to determine the
quality of included studies20. However, we decided against applying the entire tool in the
current review version. T he appraisal is challenging to apply when studying an emerging
disease with unknown pathology. For example, it is not possible to determine what
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proportion of eligible participants/patients are included in the studied populations when
the total number of infections in a given region/city is unknown. With a largely unknown
disease process, it is also difficult to determine whether the time between the exposure
and outcome is sufficient. We therefore focused on three of the 14 criteria to determine
whether studies were of sufficient quality to warrant inclusion in meta-analysis. Studies
were judged as ‘good’ quality if they: i) had low levels of missing data on smoking status
(i.e. <20%) and used a reliable self-report measure that distinguished between current,
former and never smoking status; AND ii) used biochemical verification of smoking
status and reported results from adjusted analyses; OR reported data from a
representative/random sample. Studies were rated as ‘fair’ if they fulfilled only criterion i)
and were otherwise rated as ‘poor’. T he quality appraisal was conducted by one reviewer
and verified by a second.
 
Evidence synthesis
 
A narrative synthesis was conducted. Where possible, data were pooled in R v.3.6.321 with
the Mantel-Haenszel or inverse variance method using random or fixed effects,
depending on heterogeneity, and presented as risk ratios (RRs)22. Heterogeneity
between study outcomes was assessed using the I2 statistic, suitable for smaller meta‐
analyses23.
T o aid in the visualisation of smoking prevalence in the included studies, 95% bootstrap
percentile confidence intervals were calculated for each study estimate. We performed
1,000 bootstrap replications, with the 2.5th and 97.5th percentiles of the empirical
distribution forming the 95% bootstrap percentile confidence intervals24. It should be
noted that prevalence estimates in the included studies were not adjusted for age, sex,
socioeconomic position, or region within countries.
 
Results
 
In the current review version (v5), a total of 636 new records were identified, with 148
studies included in a narrative synthesis and 23 studies included in meta-analyses (see
Figure 1).
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Figure 1. PRISMA flow diagram of included studies.
 
Study characteristics
 
Characteristics of included studies are presented in T able 1. Forty-three studies were
conducted in China, 37 in the US, 15 in the UK, nine in Mexico, nine in Spain, eight in
France, six in Italy, five across multiple international sites, two in Israel, and one each
from Brazil, Chile, Denmark, Finland, Germany, India, Iran, South Korea, Kuwait, Poland,
Portugal, Saudi Arabia, Switzerland and T urkey (see Figure 2). One-hundred-and-five
studies were conducted in hospital settings. T hirty-four studies included a community
component in addition to hospitalised patients. Seven studies were conducted exclusively
in the community, one in a quarantine centre and one did not state the study setting.
Studies had a median of 326 (interquartile range = 106-1,122) participants.
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Figure 2. Map of countries where included studies were conducted. Five studies were performed in
multiple countries and are hence not included here.
 
Smoking status
 
Categorisation of smoking status was heterogeneous (see T able 1). Ninety-two studies
collected data on smoking status through routine electronic health records, 35 studies
used a bespoke case report form for COVID-19 and 21 studies did not state the source
for information on smoking status. None of the studies verified smoking status
biochemically. Notably, only 32 (21.6%) studies reported current, former and never
smoking status, with a further 11 studies reporting current/former and never smoking
status. T he remaining 105 studies reported current, current/former or current and
former smoking status but did not explicitly state whether remaining participants were
never smokers or if data were missing on smoking status. T wenty-six studies explicitly
reported the proportion with missing data on smoking status, which ranged from 0.08%
to 96.4%.
 
Use of alternative nicotine products
 
T wo studies recorded the use of alternative nicotine products in current and/or former
smokers but did not report COVID-19 outcomes stratified by nicotine use25,26.
 
Quality appraisal
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T wenty-eight studies were rated as ‘fair’ quality due to having low levels of missing data
and distinguishing between current, former and never smoking status (see T able 1). T he
remaining 120 studies were rated as ‘poor’ quality.
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Smoking prevalence by country
 
Unadjusted smoking prevalence compared with overall estimates for national adult
smoking prevalence split by country and study setting is presented in Figure 3a and 3b.
Lower than expected current and former smoking prevalence was generally observed.
Large variability in prevalence estimates was observed across studies conducted in the
US.
 
Figure 3a. Weighted mean prevalence of current smoking in included studies with 95% bootstrap
confidence intervals compared with national current smoking prevalence (solid red lines), split by
country. Shape corresponds to study setting (community, community and hospital, hospital) and shape
size corresponds to relative study sample size.
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Figure 3b. Weighted mean prevalence of former smoking in included studies (where this was reported)
with 95% bootstrap confidence intervals compared with national former smoking prevalence (solid red
lines), split by country. Shape corresponds to study setting (community, community and hospital,
hospital) and shape size corresponds to relative study sample size.
 
SARS-CoV-2 infection by smoking status
 
T wenty-five studies provided data on SARS-CoV-2 test results for people meeting local
testing criteria by smoking status (see T able 2). Meta-analyses were performed for 12
‘fair’ quality studies (see Figure 4 and 5). Current smokers were at reduced risk of testing
positive for SARS-CoV-2 compared with never smokers (RR = 0.70, 95% CI = 0.55-0.88, p
= .003, I2 = 90%). No significant difference was observed between former and never
smokers (RR = 1.02, 95% CI = 0.92-1.12, p = .76, I2 = 72%).
 
T able 2. SARS-CoV-2 infection by smoking status.
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Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers.
 
Figure 5. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers.
 
Hospitalisation for COVID-19 by smoking status
 
T wenty-one studies examined hospitalisation for COVID-19 disease stratified by smoking
status (see T able 3). Meta-analyses were performed for seven ‘fair’ quality studies (see
Figure 6 and 7). T here was no significant difference between current and never (RR =
1.06, 95% CI = 0.79-1.44, p = .63, I2 = 79%) or former and never smokers (RR = 1.20, 95%
CI = 0.95-1.51, p = .10, I2 = 79%) in the risk of requiring admission to hospital with COVID-
19.
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T able 3. Hospitalisation for COVID-19 by smoking status.
 
 
 
Figure 6. Forest plot for risk of hospitalisation in current vs. never smokers.
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Figure 7. Forest plot for risk of hospitalisation in former vs. never smokers.
 
Disease severity by smoking status
 
Forty studies reported disease severity in hospitalised patients stratified by smoking
status (see T able 4). Severe (as opposed to non-severe) disease was broadly defined as
requiring IT U admission, requiring oxygen as a hospital inpatient or in-hospital death.
Meta-analyses were performed for six ‘fair’ quality studies (see Figure 8 and 9). No
significant difference was observed between current and never smokers (RR = 1.22, 95%
CI = 0.98-1.53,  p = .08, I2 = 22%). Former smokers were at increased risk of greater
disease severity compared with never smokers (RR = 1.58, 95% CI = 1.07-2.32, p = .02, I2
= 68%).
 
T able 4. Disease severity by smoking status.
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Figure 8. Forest plot for the risk of severe disease in current vs. never smokers.
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Figure 9. Forest plot for the risk of severe disease in former vs. never smokers.
 
Mortality by smoking status
 
T hirty studies reported mortality from COVID-19 by smoking status (see T able 5), with
five ‘fair’ quality studies included in meta-analyses (see Figure 10 and 11). Current (RR =
1.70, 95% CI = 1.14-2.55, p = .01, I2 = 29%) and former (RR = 2.00, 95% CI = 1.57-2.55, p <
.0.001, I2 = 0%) smokers were at increased risk of in-hospital mortality from COVID-19
compared with never smokers.
 
T able 5. Mortality by smoking status.
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Figure 10. Forest plot for the risk of mortality in current vs. never smokers.
 
Figure 11. Forest plot for the risk of mortality in former vs. never smokers.
 
Discussion
 
T his rapid review of 148 studies found substantial uncertainty arising from the recording
of smoking status. Notwithstanding these uncertainties, compared with overall adult
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national prevalence estimates, recorded current and former smoking rates in most
countries were lower than expected. From available data, there was insufficient evidence
to conclude that current and/or former smoking status is associated with hospitalisation.
T here was some evidence from ‘fair’ quality studies that the risk of SARS-CoV-2 infection
is reduced in current compared with never smokers. Conversely, former compared with
never smokers were at increased risk of greater disease severity in those hospitalised for
COVID-19. Both current and former smokers had increased risk of in-hospital mortality
from COVID-19 compared with never smokers.
 
Infection by smoking status
 
In 12 ‘fair’ quality studies, evidence suggests that current smokers in the community are
less likely to test positive for SARS-CoV-2 compared with never smokers. It should be
noted that criteria for accessing testing will vary during the course of the epidemic. It is
possible that current and former smokers are more likely to receive a test due to
increased prevalence of cough or altered sense of smell or taste172, which are used as
screening criteria. Infection positivity rates estimated among random samples will be
more informative than currently available data. Smoking status is being collected in at
least two large representative infection and antibody surveys in the UK173,174.
 
Hospitalisation and disease severity by smoking status
 
As reported elsewhere175, smoking prevalence among multiple hospital and community
cohorts was consistently lower than national estimates. In a single study conducted in
Korea and 15 studies of varying quality conducted in the UK, however, current and former
smoking rates were more similar to expected national estimates.
 
In seven ‘fair’ quality studies across four countries, there was no evidence that current or
former smokers are at lower risk of hospitalisation for COVID-19 compared with never
smokers among those testing positive in the community. T here was some evidence
from six ‘fair’ quality studies that former (but insufficient evidence that current) smokers
are at increased risk of greater disease severity compared with never smokers.
 
Mortality by smoking status
 
In five ‘fair’ quality studies, there was some evidence that current and former smokers
are at increased risk of in-hospital mortality from COVID-19 compared with never
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smokers. It should, however, be noted that given lack of knowledge of the disease
progression and long-term outcomes of COVID-19 disease, it is unclear whether studies
conducted thus far in the pandemic have monitored patients for a sufficient time period
to report complete survival outcomes or whether they are subject to early censoring.
 
Issues complicating interpretation
 
Interpretation of results from studies conducted during the first phase of the SARS-CoV-
2 pandemic is complicated by several factors (see Figure 11). First, exposure to SARS-
CoV-2 is heterogeneous with different subgroups at heightened risk of infection at
different stages of the pandemic. T his will likely introduce bias in studies assessing the
rate of infection by smoking status conducted early on. Second, as mentioned above,
current and former smokers may be more likely to meet local criteria for community
testing due to increased prevalence of symptoms consistent with SARS-CoV-2 infection,
such as cough, increased sputum production or altered sense of smell or taste172. T hird,
testing for acute infection requires swabbing of the mucosal epithelium, which may be
disrupted in current smokers, potentially altering the sensitivity of assays88.
 
Fourth, most included studies relied on electronic health records (EHRs) as the source of
information on smoking status. Research shows large discrepancies between EHRs and
actual behaviour176. Known failings of EHRs include implausible longitudinal changes,
such as former smokers being recorded as never smokers at subsequent hospital
visits176. Misreporting on the part of the patient (perhaps due to perceived
stigmatisation) has also been observed, with biochemical measures showing higher rates
of smoking compared with self-report in hospitalised patients in the US177. It is hence
possible that under-reporting of current and former smoking status in hospitals occurred
across the included studies. Fifth, individuals with severe COVID-19 symptoms may have
stopped smoking immediately before admission to hospital and may therefore not have
been recorded as current smokers (i.e. reverse causality).
 
Sixth, smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present
to hospital due to lack of access to healthcare and may be more likely to die in the
community from sudden complications (i.e. self-selection bias) and thus not be recorded.
Seventh, if there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt
nicotine withdrawal upon hospitalisation may lead to worse outcomes12. Eight, during
periods of heightened demand of limited healthcare resources, current and former
smokers with extensive comorbidities may have reduced priority for intensive care
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admission, thus leading to higher in-hospital mortality.
 
Another important issue is that the reason for hospitalisation varies by country and time
in the pandemic. For example, early cases may have been hospitalised for isolation and
quarantine reasons and not due to medical necessity. It is plausible that this may have
skewed early data towards less severe cases. In addition, the observed association
between former smoking and greater disease severity may be explained by collider
bias178, where conditioning on a collider (e.g. testing or hospitalisation) by design or
analysis may introduce a spurious association between current or former smoking (a
potential cause of testing or hospitalisation) and SARS-CoV-2 infection/adverse
outcomes from COVID-19 (potentially exacerbated by smoking)179.
 
Figure 11. A schematic of some of the interpretation issues for the association of smoking and SARS-
CoV-2/COVID-19. * Indicates potential confounding with smoking status.
 
Limitations
 
T his living rapid evidence review was limited by not having two independent reviewers
extracting data, limiting the search to one electronic database and one pre-print server
and by not including at least three large population surveys due to their reliance on self-
reported suspected SARS-CoV-2 infection (which means they do not meet our eligibility
criteria)172,180,181. Population surveys – particularly with linked health data – will be
included in future review versions to help mitigate some of the limitations of healthcare
based observational studies. . T he comparisons of current and former smoking
prevalence in the included studies with national prevalence estimates did not adjust
observed prevalence for the demographic profile of those tested/admitted to hospital.
Other reviews focused on this comparison have applied adjustment for sex, and continue
to find lower than expected prevalence – notwithstanding the issues complicating
interpretation described above16.  Future versions of the review will take a Bayesian
approach to the comparisons to mitigate the issue of repeating multiple meta-analyses
across different versions of this living review.
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Implications for research, policy and practice
 
Further scientific research is needed to resolve the mixed findings summarised in our
review. First, clinical trials of the posited therapeutic effect of nicotine could have
important implications both for smokers and for improved understanding of how the
SARS-CoV-2 virus causes disease in humans. Such trials should focus on medicinal
nicotine (as smoked tobacco is a dirty delivery mechanism that could mask beneficial
effects) and potentially differentiate between different modes of delivery (i.e. inhaled vs.
ingested) since this can affect pharmacokinetics182 and potential therapeutic effects. A
second research priority would be a large, representative (randomly sampled) population
survey with a validated assessment of smoking status which distinguishes between
recent and long-term ex-smokers – ideally biochemically verified – and assesses
seroprevalence and links to health records.
 
In the meantime, public-facing messages about the possible protective effect of
smoking or nicotine are premature. In our view, until there is further research, the quality
of the evidence does not justify the huge risk associated with a message likely to reach
millions of people that a lethal activity, such as smoking, may protect against COVID-19.
It continues to be appropriate to recommend smoking cessation and emphasise the role
of alternative nicotine products to support smokers to stop as part of public health
efforts during COVID-19. At the very least, smoking cessation reduces acute risks from
cardiovascular disease and could reduce demands on the healthcare system183. GPs and
other healthcare providers can play a crucial role – brief, high-quality and free online
training is available at National Centre for Smoking Cessation and T raining.
 
Conclusion
 
Across 148 studies, there is substantial uncertainty arising from the recording of
smoking status on whether current and/or former smoking status is associated with
SARS-CoV-2 infection, hospitalisation or mortality. T here is some evidence that current
smoking compared with never is associated with reduced risk of testing positive in the
community but greater in-hospital mortality from COVID-19. T here is some evidence
that former compared with never smoking is associated with increased risk of greater
disease severity and in-hospital mortality from COVID-19.
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